LIVE
TDOC
Teladoc Health, Inc. · Healthcare - Telehealth Platform
$8.07
+22.09% this month
VERSUS
⟷
COMPARE
HIMS
Hims & Hers Health, Inc. · Healthcare - Consumer Health Brand
$35.47
+58.07% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
TDOC
3
HIMS
1
Comparison scoreboard
TDOC LEADS 3/5AI Score
TDOC 24.4
HIMS ✓35.1
1Y Return
TDOC ✓+15.12%
HIMS -41.92%
Fwd P/E
TDOC ✓-12.46
HIMS 39.85
Target Up.
TDOC ✓-8.30%
HIMS -22.97%
Op. Margin
TDOC N/A
HIMS N/A
Metrics last refreshed: 6/20/2026
Quick take
TDOC vs HIMS Stock Comparison: AI Score, Valuation, Performance and Upside
TDOC (Teladoc Health) and HIMS (Hims & Hers) are both telehealth companies but with very different models — Teladoc is the B2B enterprise telehealth platform serving employers and health plans with comprehensive virtual care, while Hims & Hers is a consumer-direct health brand destigmatizing and subscription-izing men's and women's health categories. Teladoc is larger and more comprehensive; Hims & Hers is faster-growing and more consumer-brand focused.
TDOC vs HIMS is enterprise B2B virtual care platform (Teladoc's employer and insurance channel) versus consumer-direct branded health subscription business (Hims & Hers' destigmatized men's and women's health) — both in telehealth but fundamentally different go-to-market strategies and business models.
Live analysis · updated 6/20/2026
TDOC holds the edge across 3 of 5 key metrics in this comparison. TDOC leads on both 1-year return (+15.12%) and forward P/E (-12.46x vs 39.85x for HIMS), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for TDOC (-8.30%) than for HIMS (-22.97%).
Normalized 1Y performance
TDOC
HIMS
Recent returns
TDOC
HIMS
Analyst price targets & sentiment
TDOC · 20 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.5/5.0)
Price target range
analyst low$5.00
analyst high$10.00
analyst mean$7.40
current price$8.07
-8.3% upside to analyst mean
HIMS · 14 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.8/5.0)
Price target range
analyst low$21.00
analyst high$39.00
analyst mean$27.32
current price$35.47
-23.0% upside to analyst mean
Who should consider this stock?
TDOC may suit investors who:
- →Want the largest virtual care platform serving employer and health plan markets with comprehensive mental health (BetterHelp), primary care, and chronic condition management
- →Value Teladoc's B2B enterprise channel as a lower customer acquisition cost model versus consumer-direct advertising-dependent telehealth companies
- →See Teladoc's integrated care vision (one platform for all virtual health needs) as the logical destination for employers seeking to consolidate telehealth vendor relationships
HIMS may suit investors who:
- →Want a consumer health brand with high subscriber growth driven by destigmatized men's and women's health products and subscription medication management
- →Value Hims & Hers' brand differentiation in health categories (ED, hair loss, mental health) that traditional pharmaceutical companies have not marketed effectively to consumers
- →See category expansion (GLP-1, primary care, women's health) as a significant revenue growth opportunity as Hims scales its consumer health brand
Performance & AI score
| Metric | TDOC | HIMS |
|---|---|---|
| AI score | 24.4 | 35.1 |
| AI rank | #3131 | #1626 |
| Latest close | $8.07 | $35.47 |
| 1M return | +22.09% | +58.07% |
| 6M return | +11.31% | +1.43% |
| 1Y return | +15.12% | -41.92% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | TDOC | HIMS |
|---|---|---|
| 1Y ago | $11.51K (+15.1%) started 2025-06-18 | $5.81K (-41.9%) started 2025-06-18 |
| 5Y ago | $516.28 (-94.8%) started 2021-06-18 | $31.95K (+219.5%) started 2021-06-18 |
| 10Y ago | $6.23K (-37.7%) started 2016-06-20 | $36.19K (+261.9%) started 2019-09-13 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | TDOC | HIMS |
|---|---|---|
| Market cap | $1.46B | $8.21B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -12.46 | 39.85 |
| Price/Sales | 0.58 | 3.46 |
| EV/Revenue | 0.66 | 3.23 |
| Analyst target | $7.40 | $27.32 |
| Target upside | -8.30% | -22.97% |
Growth, profitability & risk
| Metric | TDOC | HIMS |
|---|---|---|
| Revenue growth | -2.50% | 3.80% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | +8.28% | +7.36% |
| Operating margin | N/A | N/A |
| Profit margin | -6.81% | -0.56% |
| ROIC proxy | -12.39% | -2.66% |
| Return on equity | -12.39% | -2.66% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 2.14 | 2.40 |
| Debt/equity | 77.68 | 253.72 |
| Current ratio | 2.80 | 1.69 |
| Quick ratio | 2.40 | 1.46 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
TDOC max drawdown52.75%
HIMS max drawdown78.06%
TDOC max wkly drop17.02%
HIMS max wkly drop32.71%
5Y risk snapshot
TDOC max drawdown97.39%
HIMS max drawdown78.88%
TDOC max wkly drop43.25%
HIMS max wkly drop39.06%
10Y risk snapshot
TDOC max drawdown98.48%
HIMS max drawdown87.29%
TDOC max wkly drop43.25%
HIMS max wkly drop39.06%
Performance metrics by period
| Period | Metric | TDOC | HIMS |
|---|---|---|---|
| 1Y | Growth | +15.12% | -41.92% |
| CAGR | +15.13% | -41.94% | |
| Sharpe ratio | 0.45 | -0.12 | |
| Max drawdown | 52.75% | 78.06% | |
| Max daily drop | 9.60% | 34.63% | |
| Max wkly drop | 17.02% | 32.71% | |
| 5Y | Growth | -94.84% | +219.55% |
| CAGR | -44.72% | +26.16% | |
| Sharpe ratio | -0.68 | 0.64 | |
| Max drawdown | 97.39% | 78.88% | |
| Max daily drop | 40.15% | 34.63% | |
| Max wkly drop | 43.25% | 39.06% | |
| 10Y | Growth | -37.68% | +261.94% |
| CAGR | -4.62% | +20.95% | |
| Sharpe ratio | 0.15 | 0.57 | |
| Max drawdown | 98.48% | 87.29% | |
| Max daily drop | 40.15% | 34.63% | |
| Max wkly drop | 43.25% | 39.06% |
Business comparison
| Category | TDOC | HIMS |
|---|---|---|
| Company | Teladoc Health, Inc. | Hims & Hers Health, Inc. |
| Sector | Healthcare - Telehealth Platform | Healthcare - Consumer Health Brand |
| Industry | N/A | N/A |
| Core business | Teladoc Health is the world's largest virtual care company, providing telehealth services including primary care, mental health (BetterHelp), chronic condition management (Livongo, for diabetes, hypertension), and specialty care through employer benefits and health insurance channels. | Hims & Hers is a consumer health company offering telehealth consultations and medications for men's health (erectile dysfunction, hair loss, premature ejaculation) and women's health (skincare, hair, sexual health, mental health) — focusing on destigmatizing and making accessible conditions that consumers have historically been reluctant to discuss with in-person doctors. |
| Investor focus | Investors track Teladoc's integrated care visit volume, BetterHelp therapy session growth and marketing efficiency, Livongo chronic condition program membership, revenue per member, and the path to profitability after heavy investment in building the integrated care platform. | Investors track Hims & Hers' subscriber count, average order value, category expansion (GLP-1 weight loss medications, mental health, primary care), revenue growth, and the sustainability of its subscription consumer health brand business model. |
TDOC strengths
- →Market-leading virtual care platform with comprehensive health services across primary care, mental health, and chronic condition management in a single integrated offering
- →Employer and health plan channel provides large enterprise customer contracts covering millions of covered lives — B2B2C distribution reduces consumer acquisition cost versus direct-to-consumer
- →BetterHelp is the world's largest online therapy platform with millions of therapy clients globally
HIMS strengths
- →Consumer brand power in the men's health and women's health categories — Hims has succeeded in destigmatizing ED and hair loss treatment through direct, non-clinical brand messaging
- →Subscription model provides recurring revenue from ongoing medication refills — most Hims & Hers customers subscribe for months or years to ongoing prescriptions
- →GLP-1 weight loss medication category (offering compounded semaglutide during drug shortage) rapidly expanded the addressable market and drove significant subscriber growth
Risks to watch — TDOC
- →Teladoc's $18.5 billion acquisition of Livongo in 2020 has not delivered expected value — the company took a massive goodwill write-down and the integrated care cross-selling has been slower than expected
- →BetterHelp marketing efficiency has declined — the consumer mental health market requires expensive direct-to-consumer advertising as the therapy category remains fragmented
- →Telehealth reimbursement regulations are still evolving — Medicare and insurance coverage for virtual visits varies and adds uncertainty to the revenue model
Risks to watch — HIMS
- →Hims & Hers's GLP-1 compounded drug business faces regulatory risk — the FDA ended the official drug shortage designation for Ozempic and Wegovy, which could limit the ability to compound generic versions
- →Consumer-direct acquisition through social media advertising is expensive — Hims depends on paid social and digital marketing to acquire subscribers at sustainable economics
- →Physician staffing and prescription practices in telehealth face ongoing regulatory scrutiny — prescribing standards for telehealth-only practitioners continue to evolve
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
More comparisons
Browse all 1,000 comparisons →